- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- open-label rifaximin, double-blind placebo, double-blind rifaximin
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 293
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 226 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2305–2328
of 7,463
matching trials from the live ClinicalTrials.gov search.
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 365 Days to 25 Years
- Enrollment
- 5,951 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2032
- U.S. locations
- 203
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ligelizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,033 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 36 more
- Conditions
- Menopausal and Female Climacteric States
- Interventions
- Other: Placebo, GSK232802, PREMARIN
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 41
- States / cities
- Chandler, Arizona • Glendale, Arizona • Scottsdale, Arizona + 35 more
- Conditions
- Major Depressive Disorder
- Interventions
- RX-10100
- Drug
- Lead sponsor
- Rexahn Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 44
- States / cities
- Cerritos, California • Escondido, California • Los Angeles, California + 38 more
- Conditions
- Major Depressive Disorder
- Interventions
- Cariprazine, Antidepressant Therapy (ADT)
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 88
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more
- Conditions
- Asthma
- Interventions
- Mepolizumab, Placebo, SOC
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 556 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more
- Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
- Interventions
- Fluorouracil, Leucovorin Calcium, Oxaliplatin, Irinotecan, Nivolumab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen Collection, Questionnaire Administration
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 795
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 510 more
- Conditions
- Chronic Graft-versus-Host-Disease, Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
- Interventions
- Not listed
- Lead sponsor
- University of British Columbia
- Other
- Eligibility
- 0 Years to 24 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 11
- States / cities
- San Francisco, California • Denver, Colorado • Atlanta, Georgia + 8 more
- Conditions
- Type 2 Diabetes
- Interventions
- Lixisenatide (AVE0010), Insulin glulisine QD, Insulin glulisine TID, Insulin Glargine (Mandatory background drug), Metformin (Background drug)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 894 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 46
- States / cities
- Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
- Interventions
- Brachytherapy, Carboplatin, Cisplatin, External Beam Radiation Therapy, Paclitaxel, Quality-of-Life Assessment
- Radiation · Drug · Other
- Lead sponsor
- GOG Foundation
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 926 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 315
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 220 more
- Conditions
- Urticaria
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 40
- States / cities
- Granada Hills, California • Long Beach, California • Los Angeles, California + 36 more
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Interventions
- docetaxel, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 73
- States / cities
- Scottsdale, Arizona • Duarte, California • Palo Alto, California + 55 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- brentuximab vedotin, doxorubicin, vinblastine, dacarbazine, G-CSF, nivolumab
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 55
- States / cities
- Fountain Valley, California • Aurora, Colorado • Colorado Springs, Colorado + 48 more
- Conditions
- Arthropathy, Hip Arthropathy, Hip Osteoarthritis
- Interventions
- Restoration Anatomic Acetabular Shell
- Device
- Lead sponsor
- Stryker Orthopaedics
- Industry
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2036
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Diabetic Neuropathy, Painful
- Interventions
- Pregabalin
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 30
- States / cities
- Hot Springs, Arkansas • La Jolla, California • Torrance, California + 19 more
- Conditions
- Pulmonary Hypertension
- Interventions
- Not listed
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Influenza
- Interventions
- Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative, Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative, Quadrivalent Influenza Vaccine, No Preservative
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 8 Years
- Enrollment
- 4,363 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 67
- States / cities
- Dothan, Alabama • Chandler, Arizona • Mesa, Arizona + 55 more
- Conditions
- Acne Vulgaris
- Interventions
- 1.2% JNJ 10229570-AAA, 2.4% JNJ 10229570-AAA, 3.6% JNJ 10229570-AAA, Vehicle control
- Drug · Other
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 431 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 18
- States / cities
- San Diego, California • Colorado Springs, Colorado • Denver, Colorado + 14 more
- Conditions
- School Located Vaccine Program
- Interventions
- School Located Vaccine (SLV) Program
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Denver, Colorado
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Interventions
- Autologous cultured mixed population of dermal cells
- Biological
- Lead sponsor
- Aderans Research Institute
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Santa Rosa, California • Denver, Colorado + 4 more
- Conditions
- Hypertension
- Interventions
- Darusentan, Darusentan Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
- Conditions
- Asthma
- Interventions
- IMA-638, placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 66 more
- Conditions
- Advanced Solid Tumors
- Interventions
- intravenous (IV) infusion
- Drug
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 11
- States / cities
- Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 8 more